Composition, form of production and packaging
? Capsules gelatinous, transparent, colorless, oblong form; the contents of the capsules are viscous liquid from golden yellow to yellow-brown color.
1 caps.
Lipoid PPL 600 600 mg,
consisting of:
phospholipids polyunsaturated from soybean lecithin 300 mg
glycerol mono / dialkonate (C14-C18) 120 mg
medium chain triglycerides 40.5 mg
soybean oil, purified 138.5 mg
? -tocopherol 1.0 mg
[PRING] soybean oil.
The composition of the capsule shell: gelatin, glycerol 85%.
10 pieces. - blisters (1) - packs of cardboard.
10 pieces. - blisters (3) - packs of cardboard.
10 pieces. - blisters (5) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
PHARMACHOLOGIC EFFECT
Hepatoprotective agent. The extract of soybean phospholipids consists of phosphatidylcholine and phosphoglycerides (on average, by 76%), while linoleic acid prevails from fatty acids. Hepatoprotective action of the drug is due to the acceleration of the regeneration of liver cells and the stabilization of cell membranes, inhibition of the oxidation of lipids and suppression of collagen synthesis in the liver. The drug normalizes lipid metabolism, reducing the level of cholesterol by increasing the formation of its esters and linoleic acid.
PHARMACOKINETICS
Studies of the pharmacokinetics of phosphatidylcholine have shown that it disintegrates in the intestine before lysophosphatidylcholine and is absorbed, mainly, in the same form. In the intestinal wall, its resynthesis to a phospholipid partially occurs, which then passes through the lymphatic vessels into the circulatory bed, part of the lyso- phosphatidylcholine disintegrates in the liver to fatty acids, choline and glycerin-3-phosphate.
In plasma, phosphatidylcholine and other phosphoglycerides bind strongly to lipoproteins and / or albumin.
Most of the introduced soybean phospholipids with a high content of them (3-sn-phosphatidyl) -choline is combined in the form of metabolites, with its own phospholipids of the body for several hours. Their excretion corresponds to the excretion of the body's own phospholipids or their metabolites.
INDICATIONS
- fatty degeneration of the liver of various etiologies;
- chronic hepatitis;
- toxic liver damage;
- cirrhosis of the liver;
- Hypercholesterolemia, ineffective diet and other non-drug measures (physical activity and weight loss measures).
DOSING MODE
The drug is intended for oral administration.
If there are no other indications, you should take 2 caps. of the preparation Resalut В® Pro 3 times / day before meals without chewing and drinking with a sufficient amount of liquid.
The duration of treatment depends on the course of the disease.
SIDE EFFECT
From the digestive system: sometimes there may be discomfort in the epigastric region, diarrhea.
Allergic reactions: in rare cases, skin rash, hives.
From the hemopoietic system: extremely rare - petechial rashes, bleeding in women in the intermenstrual period.
CONTRAINDICATIONS
- hypersensitivity to phospholipids, peanuts, soy and other components of the drug;
antiphospholipid syndrome.
With caution: children under 12 years.
PREGNANCY AND LACTATION
Data on the safety of the drug during pregnancy are absent. Therefore, use of Resolyut В® Pro should only be used if the intended benefit to the mother exceeds the possible risk to the fetus.
Data on the penetration of the drug Resalut В® Pro in breast milk is not available, therefore, if you need to use the drug Resalyut В® Pro during lactation, breastfeeding for the period of taking the drug should be discontinued.
SPECIAL INSTRUCTIONS
In one capsule of the preparation, Resalut В® Pro contains less than 0.1 XE.
Impact on the ability to drive vehicles and manage mechanisms
It is not known.
OVERDOSE
No reports of overdose and drug intoxication have been reported so far.
DRUG INTERACTION
Cases of incompatibility have not been known to date.
However, the interaction of the drug Resalyut В® Pro with coumarin anticoagulants (for example, fenprocumone, warfarin) can not be ruled out. If the appropriate combination therapy is inevitable, it may be necessary to adjust the dose of the drug.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of the reach of children, at a temperature of no higher than 25 В° C. Shelf life - 2 years. Do not use after the expiration date stated on the package.
